Literature DB >> 26159902

DNA Repair Gene Polymorphisms in Relation to Non-Small Cell Lung Cancer Survival.

Yuliang Su, Huan Zhang, Fangxiu Xu, Jinyu Kong, Herbert Yu, Biyun Qian.   

Abstract

BACKGROUND: Single nucleotide polymorphisms (SNPs) in the DNA repair genes are suspected to be related to the survival of lung cancer patients due to their possible influence on DNA repair capacity (DRC). However, the study results are inconsistent.
METHODS: A follow-up study of 610 non-small cell lung cancer (NSCLC) patients was conducted to investigate genetic polymorphisms associated with the DNA repair genes in relation to NSCLC survival; 6 SNPs were genotyped, including XRCC1 (rs25487 G>A), hOGG1 (rs1052133 C>G), MUTYH (rs3219489 G>C), XPA (rs1800975 G>A), ERCC2 (rs1799793 G>A) and XRCC3 (rs861539 C>T). Kaplan- Meier survival curve and Cox proportional hazards regression analyses were performed. SNP-SNP interaction was also examined using the survival tree analysis.
RESULTS: Advanced disease stage and older age at diagnosis were associated with poor prognosis of NSCLC. Patients with the variant 'G' allele of hOGG1 rs1052133 had poor overall survival compared with those with the homozygous wild 'CC' genotype, especially in female patients, adenocarcinoma histology, early stage, light smokers and without family history of cancer. For never smoking female lung cancer patients, individuals carrying homozygous variant 'AA' genotype of XPA had shorter survival time compared to those with wild 'G' alleles. Furthermore, females carrying homozygous variant XPA and hOGG1 genotypes simultaneously had 2.78-fold increased risk for death. Among all 6 polymorphisms, the homozygous variant 'AA' of XPA carriers had poor prognosis compared to the carriers of wild 'G' alleles of XPA together with other base excision repair (BER) polymorphisms.
CONCLUSIONS: Besides disease stage and age, the study found DNA repair gene polymorphisms were associated with lung cancer survival.
© 2015 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26159902     DOI: 10.1159/000430307

Source DB:  PubMed          Journal:  Cell Physiol Biochem        ISSN: 1015-8987


  6 in total

1.  Genetic Investigation of Polymorphic OGG1 and MUTYH Genes Towards Increased Susceptibility in Lung Adenocarcinoma and its Impact on Overall Survival of Lung Cancer Patients Treated with Platinum Based Chemotherapy.

Authors:  Amrita Singh; Navneet Singh; Digambar Behera; Siddharth Sharma
Journal:  Pathol Oncol Res       Date:  2017-12-05       Impact factor: 3.201

2.  Polymorphisms in DNA repair genes in gastrointestinal stromal tumours: susceptibility and correlation with tumour characteristics and clinical outcome.

Authors:  Gloria Ravegnini; Margherita Nannini; Vittorio Simeon; Muriel Musti; Giulia Sammarini; Maristella Saponara; Lidia Gatto; Milena Urbini; Annalisa Astolfi; Guido Biasco; Maria A Pantaleo; Nicola Venturoli; Patrizia Hrelia; Sabrina Angelini
Journal:  Tumour Biol       Date:  2016-07-27

3.  X-ray repair cross-complementing protein 1 and 3 polymorphisms and susceptibility of breast cancer in a Jordanian population.

Authors:  Mazhar S Al Zoubi
Journal:  Saudi Med J       Date:  2015-10       Impact factor: 1.484

4.  Modulation of Pathways Underlying Distinct Cell Death Mechanisms in Two Human Lung Cancer Cell Lines in Response to SN1 Methylating Agents Treatment.

Authors:  Olga Papadodima; Panagiotis Moulos; Aggeliki Koryllou; Georgia Piroti; Fragiskos Kolisis; Aristotelis Chatziioannou; Vasiliki Pletsa
Journal:  PLoS One       Date:  2016-07-28       Impact factor: 3.240

5.  Association of Base Excision Repair Gene Polymorphisms with the Response to Chemotherapy in Advanced Non-Small Cell Lung Cancer.

Authors:  Jie Dong; Xu Wang; Yu Yu; Xu Yan; Jiu-Wei Cui
Journal:  Chin Med J (Engl)       Date:  2018-08-20       Impact factor: 2.628

Review 6.  XPA: DNA Repair Protein of Significant Clinical Importance.

Authors:  Lucia Borszéková Pulzová; Thomas A Ward; Miroslav Chovanec
Journal:  Int J Mol Sci       Date:  2020-03-22       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.